It’s been a tumultuous few years for Theranos Inc., the Palo Alto, California-based company that rose to fame in 2004 for its allegedly revolutionary blood-testing technology—then crashed a decade later when The Wall Street Journal reported the tests didn’t work.

The once $9 billion company has been mired in legal problems since, which came to a head June 14 when CEO Elizabeth Holmes was indicted, along with the company’s former chief operating officer and president, on wire fraud charges by the AG’s Office in the Northern District of California.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]